Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized (Part B), Open-label (part A) or Double-blind (Part B), Active-controlled (Part B) Phase I/Ⅱa Study to Investigate the Safety, Tolerability, and Immunogenicity of GC3106 (quadrivalent cell-culture based influenza vaccine) after Intramuscular Administration in Healthy Subjects

Next Previous
Search
Trial Profile

A Randomized (Part B), Open-label (part A) or Double-blind (Part B), Active-controlled (Part B) Phase I/Ⅱa Study to Investigate the Safety, Tolerability, and Immunogenicity of GC3106 (quadrivalent cell-culture based influenza vaccine) after Intramuscular Administration in Healthy Subjects

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GC 3106A (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Sponsors GC Pharma; Green Cross

    • Most Recent Events

    • 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
    • 04 Dec 2014 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 Oct 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top